The earlier the better. The cost of health services in treating PWIDs with chronic hepatitis C: Results from a non-interventional study
Journal Title: MISSION 
Author/s: Felice Nava, Alberto Chiesa, Giovanni Strepparola, Giuseppe Pennisi, Rossano Vitali, Lucia Trevisi, Alfio Lucchini 
Year:  2020 Issue: 54 Language: English 
Pages:  0 FullText PDF:  0 KB
DOI:  10.3280/mis54-2020oa10583
(DOI is like a bar code for intellectual property: to have more infomation:  clicca qui   and here 

 
Open Access article
Click here to read the article.



The World Health Organization (WHO) has set up the elimination of hepatitis C virus (HCV) worldwide by 2030. The main aims of this study were to evaluate in HCV positive PWIDs: 1) the cost of patient’s journey of treated subjects; 2) the cost saving induced by HCV treatment for the public health system; 3) the potential cost for a national HCV elimination plan in drug users. We performed a non-interventional study including 1,333 PWIDs attending the Drug Abuse Units of the Public Health Service ASST Melegnano-Martesana (Milan, Italy), over one year (January–December 2017). The direct cost for the health services received by each patient during HCV treatment (excluding the cost of drug treatment) was collected using the electronic clinical database of the public health service.In the cohort of 1,333 patients we found 257 RNA HCV-positive PWIDs, 65 of which were treated. The mean health direct cost per each treated patient was € 1,418, while the mean the annual cost for each patient in waiting list for treatment was € 214. Considering that a HCV-positive PWID may infect within 3 years from infection at least 20 other new subjects, we may suppose that a HCV treatment may save about € 30,000 for the public health system. The study shows that HCV treatment in PWIDs can significantly reduce both individual and community health costs and that HCV elimination plans may be sustainable for the public health system by avoiding the enormous costs of the disease burden.
Keywords: HCV; Health Cost; PWIDs; DAAs; Patient’s journey

Felice Nava, Alberto Chiesa, Giovanni Strepparola, Giuseppe Pennisi, Rossano Vitali, Lucia Trevisi, Alfio Lucchini, in "MISSION" 54/2020, pp. , DOI:10.3280/mis54-2020oa10583

   

FrancoAngeli is a member of Publishers International Linking Association a not for profit orgasnization wich runs the CrossRef service, enabing links to and from online scholarly content